LBA25 Final overall survival (OS) analysis from ARCHES: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) + androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC).

MLA

Armstrong A.J., et al. LBA25 Final Overall Survival (OS) Analysis from ARCHES: A Phase III, Randomized, Double-Blind, Placebo (PBO)-Controlled Study of Enzalutamide (ENZA) + Androgen Deprivation Therapy (ADT) in Men with Metastatic Hormone-Sensitive Prostate Cancer (MHSPC). 2021. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1305109043&authtype=sso&custid=ns315887.

APA

Armstrong A.J., Iguchi T., Azad A.A., Szmulewitz R.Z., Holzbeierlein J., Villers A., Alcaraz A., Alekseev B.Y., Shore N.D., Petrylak D.P., Rosbrook B., Zohren F., Yamada S., Haas G.P., & Stenzl A. (2021). LBA25 Final overall survival (OS) analysis from ARCHES: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) + androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC).

Chicago

Armstrong A.J., Iguchi T., Azad A.A., Szmulewitz R.Z., Holzbeierlein J., Villers A., Alcaraz A., et al. 2021. “LBA25 Final Overall Survival (OS) Analysis from ARCHES: A Phase III, Randomized, Double-Blind, Placebo (PBO)-Controlled Study of Enzalutamide (ENZA) + Androgen Deprivation Therapy (ADT) in Men with Metastatic Hormone-Sensitive Prostate Cancer (MHSPC).” http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1305109043&authtype=sso&custid=ns315887.